Sacrosidase

From WikiProjectMed
Jump to navigation Jump to search
Sacrosidase
Names
Trade namesSucraid
Clinical data
Drug classEnzyme[1]
Main usesCongenital sucrase-isomaltase deficiency (CSID)[2]
Side effectsAbdominal pain, nausea, diarrhea, trouble sleeping, headache[2]
Routes of
use
By mouth
Typical dose2 ml with food[2]
External links
AHFS/Drugs.comMonograph
US NLMSacrosidase
Legal
Legal status
 ☒NcheckY (what is this?)  (verify)

Sacrosidase, sold under the brand name Sucraid, is a medication used to treat congenital sucrase-isomaltase deficiency (CSID).[2] Use may also help support the diagnosis of the condition in question.[2] It is taken by mouth each time a person eats.[2]

Common side effects include abdominal pain, nausea, diarrhea, trouble sleeping, and headache.[2] Other side effects may include allergic reactions.[2] It replace the enzyme sucrase which assists in the breakdown of sugar (sucrose) into simpler forms.[2]

Sacrosidase was approved for medical use in the United States in 1998.[2] In the United States 118 doses costa about 8,700 USD as of 2021.[3] In Europe it is an orphan medicine.[1]

Medical use

Dosage

It is taken at a dose of 17,000 units (2 ml) in those over 15 kg each time they eat.[2]

Chemistry

Sacrosidase is dispensed as a clear solution, with a pale yellow tint, which has a sweet taste. Users must take with food and patients who take Sucraid can maintain a normal diet. Sucraid is packaged in two plastic bottles, each 118ml. A scoop to measure Sucraid is included within the package.

References

  1. 1.0 1.1 "Sacrosidase". SPS - Specialist Pharmacy Service. 31 January 2017. Retrieved 9 October 2021.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 "Sacrosidase Monograph for Professionals". Drugs.com. Retrieved 9 October 2021.
  3. "Sucraid Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 9 October 2021.

External links

Identifiers: